Market Place
Sourcing Support
All News #Library
Biotech
Aprea Therapeutics To Update WEE1 Inhibitor Trial At ASCO 2026
21 Apr 2026 //
GLOBENEWSWIRE
Aprea Therapeutics Highlights APR-1051 Partial Response
30 Mar 2026 //
GLOBENEWSWIRE
Aprea Therapeutics Reveals 2025 Financials & Corporate Update
16 Mar 2026 //
GLOBENEWSWIRE
Aprea Reports 2nd PR for APR-1051 in ACESOT Trial
18 Feb 2026 //
GLOBENEWSWIRE
Aprea Therapeutics to Present at Oppenheimer Healthcare Conf
17 Feb 2026 //
GLOBENEWSWIRE
Aprea Therapeutics Bolsters DDR Patents for Cancer Therapeutics
12 Feb 2026 //
GLOBENEWSWIRE
Aprea Therapeutics Announces $5.6M ATM Offering on Nasdaq
29 Jan 2026 //
GLOBENEWSWIRE
Aprea Therapeutics Reveals Early Success In ACESOT-1051 Trial
29 Jan 2026 //
GLOBENEWSWIRE
Aprea Therapeutics Announces $3.1M At-The-Market Private
09 Dec 2025 //
GLOBENEWSWIRE
Aprea Announces BID Dosing in ATRN-119 Trial to Optimize Outcomes
11 Dec 2024 //
GLOBENEWSWIRE
Aprea: SRC Endorses 800mg ATRN-119 Dosing In Ongoing ABOYA-119 Trial
28 May 2024 //
GLOBENEWSWIRE
Aprea Unveils Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051
16 Oct 2023 //
GLOBENEWSWIRE
Aprea Therapeutics to Participate in 6th Annual DDR Inhibitors Summit
19 Jan 2023 //
GLOBENEWSWIRE
Aprea Announces Dosing of First Patient in Phase 1/2a Trial of ATRN-119
11 Jan 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.